Related Experiment Videos
Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential
Akseli Hemminki1, Minghui Wang, Tanja Hakkarainen
1Division of Human Gene Therapy, Departments of Medicine, Pathology and Surgery, University of Alabama at Birmingham, Alabama 35294-3300, USA. Akseli.Hemminki@Helsinki.Fi
Abstract:
Oncolytic virotherapy with conditionally replicating viruses is a promising approach for treating advanced cancers. Promiscuous tropism and low tumor transduction have represented limiting issues, which targeting approaches seek to overcome. An approach utilizing a secretory targeting molecule for the epidermal growth factor pathway (sCAR-EGF) has previously been shown to be compatible with replicating adenoviruses, when an E1-deleted vector was used in a dual-virus system in conjunction with a replication-competent agent. Here, we constructed a virus that replicates in cancer cells and codes for sCAR-EGF. Interestingly, the oncolytic potency of the novel agent was not improved over nontargeted controls in vitro or in vivo. These results suggest that the expression of biologically active proteins can be counterproductive to virus replication.
Insights
Oncolytic virotherapy uses viruses to treat cancer. A novel virus engineered to target cancer cells with sCAR-EGF did not improve oncolytic potency, suggesting protein expression may hinder virus replication.
Area of Science:
- Oncolytic virotherapy
- Cancer biology
- Molecular virology
Background:
- Conditionally replicating viruses show promise for advanced cancer treatment.
- Targeting strategies aim to improve virus delivery and efficacy.
- Previous studies combined targeting molecules with adenoviral vectors.
Purpose of the Study:
- To engineer a novel oncolytic adenovirus expressing a secretory targeting molecule for the epidermal growth factor pathway (sCAR-EGF).
- To evaluate the impact of sCAR-EGF expression on the oncolytic potency of the engineered virus in vitro and in vivo.
Main Methods:
- Construction of a replication-competent adenovirus encoding sCAR-EGF.
- In vitro assays to assess viral replication and cell killing.
- In vivo studies in animal models to evaluate tumor targeting and oncolytic efficacy.
Main Results:
- The engineered virus replicated in cancer cells and expressed functional sCAR-EGF.
- No significant improvement in oncolytic potency was observed compared to non-targeted controls.
- Both in vitro and in vivo results indicated that sCAR-EGF expression did not enhance therapeutic efficacy.
Conclusions:
- Expression of biologically active proteins, such as sCAR-EGF, within an oncolytic virus may be counterproductive to viral replication and oncolytic activity.
- Further research is needed to optimize targeting strategies for oncolytic virotherapy.